Soledad González's research while affiliated with Buenos Aires Ministry of Health and other places

Publications (13)

Article
Full-text available
Background Although paediatric clinical presentations of COVID-19 are usually less severe than in adults, serious illness and death have occurred. Many countries started the vaccination rollout of children in 2021; still, information about effectiveness in the real-world setting is scarce. The aim of our study was to evaluate vaccine effectiveness...
Preprint
Background Although paediatric clinical presentations of COVID-19 are usually less severe than in adults, serious illness and death have occurred. Many countries started the vaccination rollout of children in 2021; still, information about effectiveness in the real-world setting is scarce. The aim of our study was to evaluate vaccine effectiveness...
Article
This is a multicenter cohort study including consecutive, hospitalized patients ≥18 years, with moderate to severe COVID-19, carried out to evaluate the relationship between the timing of convalescent plasma administration and 28-day mortality. Data were prospectively collected between May 14, 2020 and October 31, 2020. Patients were grouped accord...
Article
Full-text available
Background A first-dose of various vaccines provides acceptable protection against infections by SARS-CoV-2 and evolution to the most severe forms of COVID-19. The recombinant adenovirus (rAd)-based vaccine, Gam-COVID-Vac (Sputnik V), was proven efficacious but information about effectiveness in the real-world setting is lacking. The aim of our stu...
Article
Full-text available
Background Convalescent plasma, widely utilized in viral infections that induce neutralizing antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might have beneficial effect. Our objective was to determine the risk factors for 28-days mortality in patients who received convalescent plasma for COVID-19 compared to thos...
Article
Full-text available
INTRODUCCIÓN : La vacunación en la provincia de Buenos Aires inició con personal de salud (PS). El objetivo de este trabajo es evaluar el impacto de la vacunación sobre la evolución de los casos de infección por SARS-CoV-2 en el PS, comparado con la de la población general (PG). MÉTODOS : Estudio obsewacional descriptivo de series temporales de ca...
Preprint
Full-text available
Convalescent plasma administration (CPA) is widely used to treat Covid-19, but its effectiveness remains controversial. Here we report the results of an Expanded Access Program of CPA in the province of Buenos Aires, Argentina. We evaluated the relationship between the timing of CPA and 28-day mortality in 4719 hospitalized patients with COVID-19 p...
Preprint
Full-text available
Background Convalescent plasma, widely utilized in viral infections that induce neutralizing antibodies, has been proposed for COVID-19, and preliminary evidence shows that it might have beneficial effect. Our objective was to compare epidemiological characteristics and outcomes between patients who received convalescent plasma for COVID-19 and tho...
Article
This is a preliminary, multicenter, retrospective cohort study, including 272 consecutive patients with CO-VID-19 admitted to hospitals in Buenos Aires Province, between May 15th and July 1st, 2020, included in an expanded access program to convalescent plasma. Our objectives were to analyze mortality and its independent risk factors, and to assess...

Citations

... 9 Although numerous countries are vaccinating children, few have authorized COVID-19vaccines for children under five, and some have restricted vaccines for children older than 12 years.10 Evidence of the efficacy or effectiveness of COVID-19 vaccines in children is limited, primarily related to mRNA vaccines, and only two studies were conducted during the Omicron outbreak.[11][12][13][14][15] To the best of our knowledge, there is no published evidence of vaccine effectiveness against COVID-19 in young children under five years. ...
... Although many countries are vaccinating children, few have authorized COVID-19 vaccines for children under 5 years of age, and some have restricted vaccines for children older than 12 years 10 . Evidence of the efficacy or effectiveness of COVID-19 vaccines in children is limited, primarily related to mRNA vaccines, and only two studies were conducted during the Omicron outbreak [11][12][13][14][15] . To our knowledge, there is no published evidence of vaccine effectiveness against COVID-19 in young children under 5 years of age. ...
... The early transfusion of CP to patients with COVID-19 provides more therapeutic benefits. A multicenter, cohort study from Argentina demonstrated that CP transfusion within 3 days decrease the mortality rate [26,27]. ...
... Si bien se han realizado importantes avances en los ámbitos de protección social y vacunación (Luzuriaga et al., 2021), el desarrollo de la pandemia sigue presentando olas de contagio basadas en nuevas variantes, lo que confi gura una sensación de incertidumbre frente a la gestión del riesgo. Además, se ha observado con preocupación la resistencia al proceso de vacunación, que han manifestado diferentes grupos de personas, sobre la base de las posibles consecuencias en el control de la pandemia (Galindo-Santana & Molina-Águila, 2020). ...
... A c c e p t e d M a n u s c r i p t 7 and 84.8% effectiveness for preventing SARS-CoV-2 infection and COVID-19-related death, respectively, in 60-79-year-old vaccinees as conducted in Argentina (75). Because of the shortage in the supply of vaccines, Sputnik Light was developed with a single-dose immunization of a recombinant adenovirus type 26 vector expressing the SARS-CoV-2 S protein. ...
... En este ensayo, se administró el plasma dentro de las primeras 72 horas del inicio de síntomas y arrojó resultados que mostraron una eficacia del 73% cuando los títulos de IgG administrados correspondían a una media superior a 1/3200 [7], sin mostrar efectos adversos. Asimismo, se realizaron ensayos clínicos adicionales en nuestro país para evaluar la utilidad del uso de plasmas, entre los que se puede mencionar un estudio coordinado por el Ministerio de Salud bonaerense, que mostró que la administración de plasma se asoció a una reducción en la mortalidad de pacientes con neumonía [8]. ...
... Cenci used the blood of a patient who had recovered from measles to successfully protect four children from measles, even as their uninoculated cohabitating siblings became ill [128]. Since then, CPT has been used countless times as a first line of therapy against epidemic and pandemic virus outbreaks including, notably, the Spanish influenza epidemic of 1916-1918 [129], SARS in 2004 [130,131], influenza A H1N1 pandemic of 2009 [132], Ebola in 2014 [133,134], MERS in 2015 [135] and, most recently, COVID-19 [136][137][138][139][140][141][142][143][144][145]. ...
... Keywords: convalescent plasma therapy, COVID-19, SARS-CoV-2, passive antibody transfer, Kaplan-Meier analysis INTRODUCTION In response to the coronavirus disease 2019 (COVID- 19) pandemic caused by the novel human severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), convalescent plasma has been used worldwide to treat hospitalized patients and prevent progression of disease in non-hospitalized patients (1)(2)(3)(4). Due to the limited number of therapeutic alternatives for COVID-19, widespread optimism for antibody therapy has also led to the commercial production of other immunoglobulin therapies, including monoclonal antibodies and hyperimmune products (5,6). However, despite global usage, clinicians and researchers have struggled to reach consensus regarding the clinical utility of convalescent plasma. ...
... During the SARS-CoV-2 pandemic, preliminary results from several therapeutic options have raised hopes that subsequent clinical experiences have revealed to be wrong 10 . Moreover, concerning the CCP efficacy, the lack of univocal evidence is probably due to the variety of experimental designs reported in the literature, and even today it is not certain whether it could still give a relevant contribution to the treatment of COVID-19 (Table I) [11][12][13][14][15][16][17][18] . A randomized controlled trial has been also conducted on 487 patients in Italy, named TSUNAMI Study (TranSfUsion of coNvalescent plAsma for the treatment of severe pneuMonIa due to , under the patronage of the Italian Medicine Agency (AIFA) and the Italian National Institute of Health (ISS), whose definitive results are not yet published. ...
... Several nonrandomized studies indicated that CP treatment for patients with COVID-19 may be safe, [4,8,9] with variable results regarding mortality and clinical markers of critical illness. [10][11][12] Moreover, when combined with remdesivir, CP did not improve outcomes over remdesivir alone. ...